secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001104659-23-006492
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NCCN guidelines updated to recommend PEDMARK for reducing cisplatin-induced hearing loss in pediatric AYA patients.
--------------------------------------------------------------------------------

- NCCN AYA Oncology guidelines now recommend PEDMARK to reduce cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors.
- PEDMARK, FDA-approved Sept 2022 and commercially launched Oct 2022, is first and only therapy for this indication.
- Hearing loss occurs in ~60% (up to 90%) of children treated with cisplatin; PEDMARK may reduce risk based on Phase 3 trials.
- FDA labeling states PEDMARK is not substitutable with other sodium thiosulfate products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923006492/0001104659-23-006492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923006492/tm234393d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-006492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer